Рынок стартапов
← Все стартапы
Valink Therapeutics

Valink Therapeutics

YCW21

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

/ 100
О компании

Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.

Команда
15 чел.
Статус
Active